En Bloc Resection of Thoracic Tumors Invading the Spine: A Single-Center Experience.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
07 2019
Historique:
received: 10 09 2018
revised: 07 02 2019
accepted: 08 02 2019
pubmed: 20 3 2019
medline: 8 10 2019
entrez: 20 3 2019
Statut: ppublish

Résumé

Vertebral involvement by a thoracic tumor has long been considered as a limit to surgical treatment, and despite advances, such an invasive operation remains controversial. The aim of this study was to characterize a single-center cohort and to evaluate the outcome, focusing on survival and complications. We retrospectively reviewed the data of all patients operated on for tumors involving the thoracic spine in an 8-year period. En bloc resection was generally performed by a double team involving thoracic and orthopedic surgeons. Distant follow-up was recorded for oncologic and functional analysis. There were 31 patients operated on. An induction therapy was administered in 20 patients. Spinal resection (mostly including ≥2 vertebral levels) was combined with lobectomy in 48.3% of the patients, and osteosynthesis was required in 22 patients. We observed no in-hospital death and a major complications rate of 32.3%, including 5 patients with early neurologic complications. There were 61.3% primary lung carcinomas, 12.9% extrapulmonary primaries, 9.7% metastases, and 16.1% benign tumors. Mean follow-up was 32.1 months. The 5-year overall survival rate was 81.3% in the entire cohort and 75.0% in patients with a malignant tumor. Occurrence of an early postoperative major complication was the only factor significantly associated with shorter overall survival (p = 0.03). The 5-year disease-free survival rate was 37.0% in malignancies. Delayed complications occurred in 35.5% of patients, including persistent neurologic deficit in 12.9%, instrumentation migration in 19.4%, and local infection in 12.9%. En bloc resection of spinal thoracic tumors offers long-term survival and few recurrences in highly selected patients but is associated with significant delayed mechanical or infectious complications.

Sections du résumé

BACKGROUND
Vertebral involvement by a thoracic tumor has long been considered as a limit to surgical treatment, and despite advances, such an invasive operation remains controversial. The aim of this study was to characterize a single-center cohort and to evaluate the outcome, focusing on survival and complications.
METHODS
We retrospectively reviewed the data of all patients operated on for tumors involving the thoracic spine in an 8-year period. En bloc resection was generally performed by a double team involving thoracic and orthopedic surgeons. Distant follow-up was recorded for oncologic and functional analysis.
RESULTS
There were 31 patients operated on. An induction therapy was administered in 20 patients. Spinal resection (mostly including ≥2 vertebral levels) was combined with lobectomy in 48.3% of the patients, and osteosynthesis was required in 22 patients. We observed no in-hospital death and a major complications rate of 32.3%, including 5 patients with early neurologic complications. There were 61.3% primary lung carcinomas, 12.9% extrapulmonary primaries, 9.7% metastases, and 16.1% benign tumors. Mean follow-up was 32.1 months. The 5-year overall survival rate was 81.3% in the entire cohort and 75.0% in patients with a malignant tumor. Occurrence of an early postoperative major complication was the only factor significantly associated with shorter overall survival (p = 0.03). The 5-year disease-free survival rate was 37.0% in malignancies. Delayed complications occurred in 35.5% of patients, including persistent neurologic deficit in 12.9%, instrumentation migration in 19.4%, and local infection in 12.9%.
CONCLUSIONS
En bloc resection of spinal thoracic tumors offers long-term survival and few recurrences in highly selected patients but is associated with significant delayed mechanical or infectious complications.

Identifiants

pubmed: 30885851
pii: S0003-4975(19)30356-X
doi: 10.1016/j.athoracsur.2019.02.019
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

227-234

Informations de copyright

Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Xiao-Miao Zhang (XM)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France; Department of Thoracic Surgery, Shanghai General Hospital affiliate to Shanghai Jiao Tong University, Shanghai, China.

Ludovic Fournel (L)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Audrey Lupo (A)

Department of Pathology, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Emelyne Canny (E)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Antonio Bobbio (A)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Salomé Lasry (S)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Jean-François Regnard (JF)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Frederic Sailhan (F)

Department of Orthopedic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France.

Marco Alifano (M)

Department of Thoracic Surgery, Paris-Center University-Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Descartes University, Paris, France. Electronic address: marco.alifano@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH